Last reviewed · How we verify

EVO100 — Competitive Intelligence Brief

EVO100 (EVO100) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Spermicide. Area: Contraception.

phase 3 Spermicide Contraception Small molecule Live · refreshed every 30 min

Target snapshot

EVO100 (EVO100) — Evofem Inc.. EVO100 is a vaginal contraceptive film that provides non-hormonal contraception through a spermicidal mechanism.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
EVO100 TARGET EVO100 Evofem Inc. phase 3 Spermicide
Benzalkonium Chloride Spermicide Cream Benzalkonium Chloride Spermicide Cream Laboratoire Innotech International marketed Spermicide

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Spermicide class)

  1. Evofem Inc. · 1 drug in this class
  2. Laboratoire Innotech International · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EVO100 — Competitive Intelligence Brief. https://druglandscape.com/ci/evo100. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: